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Purpose: This report reviews our preliminary experience ofprospective treatment of arterial 
lesions with endoluminal grafts in a Food and Drug Administration (FDA)-approved, 
investigator-sponsored Investigation Device Exemptions study. The utility and accuracy of 
various imaging methods, including angiography, cinefluoroscopy, computed tomography 
(CT), intravascular ultrasonography (IVUS), and duplex scanning, in performing the 
procedures was also assessed. 
Methods: Thirty-one patients were evaluated; 17 patients were treated, including 11 with 
abdominal aortic anetlrysms, one with an aortic occlusive lesion, two with iliac artery 
aneurysms, and three with traumatic arteriovenous fi tulas. Twelve of the 14 patients who 
had aorta and iliac artery lesions were high-risk. The mean follow-up of patients treated 
was 9 months (range, 6 to 15 months). 
Results: Aortoaortic endoluminal interposition procedures were not successfill for treating 
abdominal aortic aneurysms early in the study (n = 3). Aortoiliac endoluminal bypass, 
contralateral iliac artery occlusion, and femorofemoral bypass procedures were successful 
in seven of eight subsequent cases (88%), with no incidence of endoleaks at either the 
proximal or distal fixation sites using the deployment methods described in this report. The 
30-day operative mortality rate on follow-up evaluations for patients who underwent 
aortoiliac procedures was 14% (two of 14). Other major complications included transient 
renal failure in three patients that required short-term (two to eight times) dialysis, one 
arterial perforation and one dissection, and one prolonged intubation. No myocardial 
infarctions or strokes occurred. After major complications or identification of limitations 
in the study, the protocol was modified with the approval of the FDA to help avoid the 
recurrence of the same problems. There were no deaths or complications in the trauma 
cases. 
Conclusions: Contrast-enhanced CT (axial images and spiral reconstructions) was the 
most accurate method to determine candidacy for aortoiliac procedures and to choose 
the site for deployment of the devices. Angiographic scans were misleading in several 
patients regarding the critical determinants of patient candidacy and device deployment, 
particularly regarding the presence of a distal aortic neck. Cinefluoroscopy was used 
in all patients and was particularly useful for determining the continuity of vascular 
structures and the anatomy of branch arteries and for enabling precise positioning of stent 
devices. Determination of fixation sites and assessing dimensional information by 
cinefluoroscopy and angiography were limited by inaccuracies produced by image 
magnification, parallax, and uniplanar views. IVUS was used to determine the morpho- 
logic features of vascular structures (i.e., calcium, thrombus), to perform real-time 
observation of the expansion of devices, and to assure firm fixation of balloon-expanded 
stents before the procedures were completed. Duplex scanning was very helpful in assessing 
and identifying precisely the location of arteriovenous fistulas before intervention and 
provided assessment a follow-up intervals. Three-dimensional reconstruction imaging 
technologies such as spiral CT were particularly helpfill for assessing the morphologic 
features of vascular anatomy before the intervention and at follow-up intervals, whereas 
3-D IVUS provided a similar real-time perspective during the procedure. (J Vase Surg 
1996;24:556-71.) 
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Endovascular prosthetic treatment of vascular 
lesions is being performed in many countries with 
variable monitoring mechanisms. Many devices are 
being fabricated by combining available stents and 
vascular graft materials. The widespread interest in 
these devices has been encouraged by promising 
preliminary clinical series that have reported minimal 
intervention, shorter disability and recovery periods, 
and the potential for shorter, less-costly hospital- 
ization. 1-5 
Because there arc no commercially available cn- 
dovascular prostheses and only limited access to 
investigational devices through regulatory agen- 
cy-approved studies, many procedures are being 
performed with devices in an "off-label" or "com- 
passionate use" indication. Off-label refers to the use 
of a device for indications other than those that have 
been approved for inclusion in the package labeling, 
and for the purposes of this manuscript compassionate 
use describes nonapproved use of devices in emergen- 
cies or for conditions for which no alternative therapy 
exists. 
In the United States, the Food and Drug Admin- 
istration (FDA) is charged by Congress to regulate the 
evaluation and approval of new devices and indica- 
tions for use. The agency regulates the initial use of 
significant-risk devices by a process known as Inves- 
tigational Device Exemptions (IDE) that provides for 
the legal shipment and use of unapprovcd products, 
promoting a safe investigation. 6 Manufacturers ou- 
tinely use IDEs to define patient populations that 
benefit from the new technology and to determine 
safety and efficacy requirements toobtain approval to 
market a device. Individual investigators are also 
eligible to obtain feasibility IDEs that permit assess- 
ment of new high-risk devices. For investigators who 
are studying the combination of two high-risk de- 
vices, as in the fabrication of an endoluminal graft, the 
FDA requires both IDE and Institutional Review 
Board (IRB) approval. This study was conducted with 
From the Departments ofSurgery, and the Department of Radi- 
ology (Drs. Walot and Mehringer), Harbor-UCLA Medical 
Center; and the Department ofSurgery, Wadswords VA Medical 
Center, West Los Angeles. 
Supported in part by Cardiovascular Concepts Inc., Cupertino, 
Calif.; Hewlett Packard Co., Andover, Md.; Johnson & Johnson 
Interventional Inc., Warren, N.J.; and Quinton Instrument Inc., 
Sunnyvale, Calif. 
Presented at the Eleventh Annual Meeting of the Western Vascular 
Society, Laguna Niguel, Calif., Jan. 21-24, 1996. 
Reprint requests: Rodney A. White, MD, Harbor-UCLA Medical 
Center, 1000 W. Carson St., Torrance, CA 90509. 
Copyright © 1996 by The Society for Vascular Surgery and 
International Society for Cardiovascular Surgery, North Ameri- 
can Chapter. 
0741-5214/96/$5.00 + 24/6/75185 
patient selection criterion and a device and procedural 
protocol outlined in an approved Investigator Feasi- 
bility IDE. 
METHODS 
The Feasibility IDE governing this study has two 
hypotheses. The first is to prospectively evaluate all 
patients who are candidates for cndograft treatment 
(patients who have aneurysms, arteriovenous fi tulas, 
or occlusive disease) to assess the technical feasibility 
of the endovascular placement of prostheses invessels 
that have different pathologic lesions. Additional 
aspects of this objective are to develop appropriate 
questions for future investigations, to determine criti- 
cal issues in device design and deployment, toevaluate 
adverse reactions and failures and recommend im- 
provements, and to determine whether educing the 
invasiveness of the therapy improves the quality of 
care compared with historical control data. The 
second objective of the study is to determine the 
optimal imaging methods for the deployment of 
endovascular devices--in particular, the role that 
intravascular ultrasound (IVUS) has as an alternative 
or complementary method to cinefluoroscopy. 
The study compared the relative utility of various 
imaging methods, including angiography, cinefluo- 
roscopy, computed tomography (CT), IVUS, and 
duplex scanning, in the various aspects of endograft 
application. As limitations or complications of the 
procedures became apparent, or as new technology 
that could increase the safety and utility of the method 
became available, the protocol was amended with the 
approval of the FDA to incorporate the appropriate 
changes. 
Thirty-one patients were evaluated for inclusion 
in the study. The majority of the patients entered in 
the protocol were referred because they were iden- 
tified as candidates who had lesions amenable to 
treatment by the available device. Candidates were 
chosen on the basis of evaluation of angiograms and 
CT scans. Angiograms were available for evaluations 
in all but one patient, and contrast CT images were 
required for all aortoiliac procedures, with spiral CT 
performed when possible. Shaded surface-rendered 
spiral CT images were available for the last eight 
aortic aneurysm patients and were acquired on a 
Picker PQ-2000 Spiral Scanner and Voxel work sta- 
tion and softwaxe (Picker International, Cleveland, 
Ohio). Eligible patients were both normal-risk and 
high-risk surgical candidates, although the majority 
were high-risk. 
Seventeen patients (11 who had abdominal aortic 
aneurysms, two who had iliac artery aneurysms, one 
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who had an aortic occlusive lesion, and three who had 
traumatic pseudoaneurysms and/or  arteriovenous 
fistulas) were entered into the study after extensive 
discussion of the procedure with the patient and 
available family members and completion of a consent 
form approved by the FDA and IRB. Patients also 
signed consent forms for conventional surgical pro- 
cedures in the event that conversion was necessary. 
Patient demographics 
Eleven patients who had abdominal aortic aneu- 
rysms (AAA) were treated in this study (10 men, one 
woman; average age, 74 years; range, 58 to 86 years). 
Nine of the AAA patients were high-risk (six cardiac 
insufficiency, one pulmonary insufficiency taking 
home oxygen for 3 years, one renal insufficiency on 
dialysis for 3 years, two chronic aortic perforations or 
pseudoaneurysms, and three patients older than 80 
years). Dimensions of the abdominal aortic aneu- 
rysms that were treated in this study were an average 
of 5.5 cm (range, 4.4 to 6.5 cm). Four patients who 
had AAAs also had iliac artery aneurysms; one of these 
patients had bilateral aneurysms extending to the 
bifurcation of the common iliac arteries. The patient 
who had the smallest AAA (4.4 cm) was entered into 
the study to treat a 3.8-cm left iliac artery aneurysm 
that had no proximal neck so that simultaneous 
aortoiliac exclusion of both aneurysms was the best 
available treatment. Two high-risk male patients (av- 
erage age, 78 years) who had unilateral i iac artery 
aneurysms were treated (one with cardiac and renal 
insufficiency, and one patient on home oxygen for 31/2 
years). One additional high-risk 70-year-old woman 
who had cardiac insufficiency and an 85% infrarenal 
aortic occlusive lesion was treated in this study. Three 
additional male patients (average age, 21 years) had 
traumatic arterial injuries from gunshot wounds (two 
axillary artery pseudoaneurysms with one arterio- 
venous fistula, and one profunda rtery-femoral vein 
arteriovenous fi tula). 
Prosthesis design 
The endovascular prostheses that were used in this 
study were fabricated by combining available vascular 
stents (Johnson & Johnson Interventional, Inc., War- 
ren, N.J.) and vascular prostheses (Meadox Medical, 
Inc., Oakland, N.J.). Vascular stents included com- 
mercially available 308 Palmaz stents for smaller- 
diameter vessels and 4-cm length 4014 and 4015 
extra-large Palmaz stents, which were approved for 
use by an amendment tothe IDE, for larger-diameter 
aortic devices. Cooley-VeriSoft tubular and bifur- 
cated vascular prostheses (Meadox) were used for 
aortoiliac lesions. Crimps in the fabric were removed 
by heat pressing. Autogenous veins were harvested for 
the smaller-diameter raumatic lesions. Fabric stent- 
graft prostheses were fabricated by securing stents to 
the grafts with 4-0 and 5-0 polytetrafluoroethylene 
(PTFE) sutures with a technique similar to one 
described by Parodi. 7 Aortic prostheses were prepared 
both in aortoaortic interposition and in aortoiliac 
configurations. Aortoaortic grafts were prepared by 
securing extra-large Palmaz stents to the ends of 20 
to 24 mm internal diameter tubular grafts. The 
aortoiliac prostheses were prepared by amputating 
one limb of a bifurcated prothesis and oversewing the 
stump with 4-0 PTFE suture. An extra-large Palmaz 
stent was sutured to the aortic end of the prosthesis 
with the distal end of the graft being secured by a 308 
Palmaz stent after deployment of the device. Con- 
tralateral iliac artery occlusion devices were prepared 
by suturing appropriate-sized vascular grafts to a 308 
Palmaz stent and ligating the aortic end of the device 
to enable vascular interruption. Smaller-diameter ar-
terial traumatic lesions were repaired by suturing the 
ends of an autologous vein to the ends of a 308 
Palmaz stent with 6-0 PTFE suture. 
Technique of endoluminal 
prosthesis deployment 
Procedures were performed in an endovascular 
interventional suite or in an operating room, with the 
patients prepped and draped in a manner similar to 
preparation for a conventional surgery. The proce- 
dures were begun by making incisions over appropri- 
ate access vessels: bilateral groin incisions for the 
aortoiliac or femoral artery lesions and brachial artery 
isolation for axillosubclavian interventions. 
Aortic prosthesis deployment technique. Ex- 
cept for the first patient reatcd in this series, when 
appropriate IVUS instrumentation was not available, 
procedures were performed with the following se- 
quence of cinefluoroscopy and IVUS imaging. This 
method deviates from protocols developed by other 
investigators where techniques for identifying fixation 
sites and performing fluoroscopic-guided deploy- 
mcnt alone have been developed with acceptable 
precision. 5 The methods we used were based on 
preliminary experimental data using IVUS as a 
method to complement conventional f uoroscopic 
techniques and was part of the feasibility data to 
support he methods approved in this IDE. s 
To begin the interventions, patients were antico- 
agulated with 5000 U of heparin and a 10F to 14F 
hemostatic sheath was introduced through an arteri- 
otomy. The length of the vessel being treated was 
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crossed with a 0.025-in Glidewire (Meditech, Inc., 
Natick, Mass.), and the Glidewire then was replaced 
with an angiographic catheter. A 0.025-in Platinum 
Plus guidewire (Meditech) was inserted through the 
length of the angiographic catheter, the catheter was 
removed, and an IVUS catheter (3.5F 20 or 30MHz, 
or 6.2F 12MHz; Meditcch) was passed along the 
wire throughout the entire length of the pathologic 
segment. 
IVUS images were obtained along the length of 
the vascular segment being treated with an HP 
SONOS IVUS imaging system (Hewlett Packard, 
Andover, Mass.). Longitudinal grey-scale and 3-D 
reconstruction of the axial IVUS images were ac- 
quired during timed catheter withdrawals with an 
IVUS image processing workstation with analysis 
software (InterVIEW, Quinton Instruments, Inc., 
Sunnyvale, Calif.). The location of relevant branch 
vessels, uch as the renal arteries, related to a ruler that 
had been placed beneath the patient were then 
identified with cinefluoroscopy. Vessel ocation rela- 
tive to the ruler was determined atthe center of the 
fluoroscopy image/screen to limit artifacts caused by 
imaging parallax. Corresponding dimensions of the 
proximal and distal fixation sites for the endoluminal 
prostheses were determined with the IVUS. The 
length of the endograft was determined by measuring 
the distance the 1VUS catheter was withdrawn from 
the proximal to the distal fixation sites. 
After determination f the appropriate diameters 
at the proximal and distal fixation sites and the length 
of the endograft, he prosthesis was assembled. The 
stent on the proximal end of the endoluminal device 
was secured to an appropriate-size balloon catheter 
for delivery and deployment of the prostheses. The 
balloons used in this study were either PEMT balloon 
angioplasty catheters (Meditech) for vessels in the 
range of 6- to 20-mm diameter, or 24-ram diameter 
by 8-cm length PET coextruded balloon dilation 
catheters (Meditech). The larger balloons used in the 
study were approved by amending the protocol as 
they became available to enable the deployment ofthe 
extra-large Palmaz stents. To facilitate low-profile 
catheter delivery, the endoluminal prostheses were 
tightly wrapped along the length of the angioplasty 
catheter, and the devices were gently back-loaded into 
the lumen of 14F to 22F Desilet-Hoffman introducer 
sheaths (Cook, Inc., Bloomington, Ind.). The sheaths 
were advanced over the endografts o approximately 
2 cm from the tip of the balloon catheter. A small 
amount of saline solution was used to inflate the end 
of the balloon to fashion atapered atraumatic end to 
the delivery system. 
Before deploying the endograft, contrast cinefluo- 
roscopy images were acquired to confirm the location 
of the proximal and distal fixation sites and branch 
vessels that had been previously identified by IVUS. 
The endoluminal prosthesis delivery systems were 
then guided through the length of the lesions with 
appropriate-size guidewires. For the aortic deploy- 
ments, a0.038-in Amplatz Superstiffwire (Meditech) 
was used. The device was advanced to position the 
proximal stent at the predetermined deployment si e. 
The introducer sheath was then retracted, and the 
balloon was inflated to deploy the proximal stent. The 
balloon catheter was then deflated. During the aortic 
interventions, the guidewire was removed and con- 
trast was injected through the distal end of the balloon 
catheter to confirm that he proximal end of the pros-. 
thesis was positioned appropriately. The guidewire 
was replaced, the introducer sheath was withdrawn 
beyond the end of the endograft, and the remainder of 
the prosthesis was dilated by the balloon. The distal 
end of the prosthesis was then secured by inflating a 
308 Palmaz stent delivered by an appropriate-size bal- 
loon catheter. In one patient who had bilateral iliac 
artery aneurysms that extended to the bifurcation of 
the common iliac arteries, an endoluminal graft anas- 
tomosis was made through an arteriotomy, preserving 
the external and hypogastric arteries and functioning 
as the origin for an iliofemoral bypass to revascularize 
the contralateral limb. 
After completion of the device deployment, the 
entire length of the endograft was visualized with 
contrast agent hrough an angiographic catheter that 
had been passed along the length of the guidewire and 
the guidewire removed. The angiographic catheter 
was then replaced by 0.025-in Platinum Plus wire and 
the IVUS catheter was introduced, the length of the 
repair interrogated to determine the continuity of the 
prosthesis and to assure fixation of the proximal and 
distal sites and exclusion of the treated lesion. 
To complete the procedures, the contralateral iliac 
artery above the hypogastric artery orifice was oc- 
cluded with an endoluminal occlusion device that was 
passed retrograde through an arteriotomy in the 
femoral artery. A femorofemoral bypass was then 
performed to complete revascularization of the limb 
contralateral to the aortoiliac endoluminal bypass. 
Real-tlme IVUS deployment technique. For 
smaller-diameter arterial lesions treated in this study, 
an alternate deployment technique with real-time 
IVUS imaging was used. This method was used for 
the deployment of the endografts for the three 
traumatic arteriovenous fistulas and the two iliac 
artery aneurysms. The IVUS-guided deployment of
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the devices was accomplished by passing the appro- 
priate-size PEMT balloon (as determined by initial 
IVUS and angiographic maging) and delivery cath- 
eter containing the endoluminal graft to the deploy- 
ment site over an appropriate-size guidewire. After 
placement of the prosthesis in the desired location, 
the guidewire was removed and a 0.035-in 30-MHz 
ultrasound" wire (WiseWire, Meditech) was passed 
through the balloon catheter guidewire lumen. The 
imaging element on the end of the wire then was used 
to observe the placement of the proximal stent device 
in the desired location and to assure complete xpan- 
sion of the prosthesis at the chosen location. The 
deployed evice was interrogated while the balloon 
was completely inflated and also after deflation of the 
balloon before it was removed. Further balloon infla- 
tions were performed as necessary to completely 
expand and secure the endograft. A final inspection 
along the length of the treated segment was made at 
the time of balloon withdrawal by inserting the 
WiseWire imaging element to a point beyond the end 
of balloon catheter and performing a continuous axial 
and 3-D reconstruction f the images during catheter 
withdrawal. 
In instances in which the real-time IVUS deploy- 
ment was possible, contrast cinefluoroscopy was lim- 
ited to images that were needed to confirm the 
anatomy of adjacent structures and to provide intralu- 
minal contrast evaluation of the completed proce- 
dures. With this technique, the amount of contrast 
agent used during the procedures was limited to only 
essential images with the entire procedure (preinter- 
vention selection of deployment site, device deploy- 
ment, and postprocedure inspection) being per- 
formed by IVUS. 
Postprocedure evaluation 
At the completion of the procedures, blood that 
had been collected by the in-line autotransfusion 
devices was reinfused into the patient. The patients 
were observed in the intensive care unit after the 
procedures. Pulses and Doppler pressures in the 
affected extremities were documented and compared 
with measurements from the preintervention evalua- 
tions. In nine cases, acontrast CT examination of the 
repair was performed 2 to 6 days after the procedure 
to inspect he continuity of the repair and to observe 
for endoleaks. For patients who had transient renal 
failure as a contraindication to CT examination, a 
duplex scan was used to confirm the position and 
function of the endoprosthesis. 
After discharge from the hospital, patients were 
reevaluated at 3-month, 6-month, and i-year inter- 
vals. Follow-up visits included gathering information 
regarding the occurrence of new cardiovascular o  
systemic events, vascular status, and the patients' 
activity level compared with the preintervention 
physical examination, including ankle-brachial in- 
dexes (ABIs) and duplex ultrasound evaluation of the 
endoluminal exclusion. At 1 year, or if the duplex 
exam did not demonstrate needed information re- 
garding function of the device at intervals less than 1 
year or if duplex scan suggested a leak, a contrast CT 
or magnetic resonance imaging (MRI) examination 
was conducted. An angiogram was obtained only if 
the duplex, CT, or MRI examinations did not provide 
required information. 
RESULTS 
Thirty-one patients were evaluated for entry into 
this study. The selection criteria included a require- 
ment for an adequate length and size of proximal 
fixation site for the device, adequate distal vasculature 
to provide adequate blood flow after the procedure, 
ability and willingness of the patient o be observed 
over a 2-year interval, and an expected 2-year survival. 
Seventeen of the 31 patients were treated; 11 with 
abdominal aortic aneurysms, two with iliac artery 
aneurysms, one with an aortic occlusive lesion, and 
three with traumatic arterial injuries. Mean follow-up 
of the patients treated was approximately 9 months 
(range, 6 to 15 months). The average length of 
hospitalization after the procedure for inpatients 
successfully treated with endografts was 6 days (range, 
4 to 17 days). 
The abdominal aortic procedures and iliac artery 
aneurysm repairs are analyzed together; 12 of the 14 
patients were high-risk. Of these patients, 12 were 
successfully treated with endoluminal prostheses, 
whereas two were converted to aortobifemoral bypass 
procedures. The two conversions occurred in patients 
who had arterial perforations. One was an iliac artery 
injury that was sustained after persistent attempts to 
seal a leak in the distal fixation site of an aortoaortic 
interposition device, and the second resulted from a 
juxtarenal aortic perforation at the site of proximal 
stent deployment. 
The complications that were encountered in the 
aortic and iliac artery aneurysm exclusion procedures 
are listed in Table I. Cardiac complications were 
limited to two instances of arrhythmia that required 
drug therapy. Both of these pisodes were recurrences 
of arrhythmias that the patients had experienced 
before intervention and did not prolong hospital stay. 
There were no myocardial infarctions, strokes, or 
transient ischemic attacks. 
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Two patients died within the first 30 days after the 
deploymcnt of aortic cndografts. The first died 4 
hours after the procedure from hemorrhage from an 
excluded chronic perforation of the abdominal orta. 
A second patient, who had chronic obstructive pul- 
monary disease and a history of home oxygen depen- 
dence, died unexpectedly after aspiration and subse- 
quent cardiac arrest 17 days after the procedure. In 
this patient, the procedure had been prolonged by 
malpositioning ofthe proximal stent when cincfluo- 
roscopy imaging was temporarily ost during device 
deployment asa result of overheating ofthe imaging 
unit. A second device was required to correct he 
malalignment and increased the procedure time by 
approximately 2 hours. Although the procedure was 
completed with regional anesthesia and the patient 
never required intubation, the additional time that 
was required to deploy the second device may have 
adversely affected his recovery. The two deaths within 
30 days of the procedure represent a 14% (two of 14) 
operative mortality rate. 
Renal complications occurred in five patients. 
These included two patients who had transient in- 
creases in creatinine level and blood urea nitrogen 
level that returned to normal without reatment, and 
three patients who required limited dialysis (two to 
eight times); all eventually recovered their baseline 
renal function. The first patient, who required renal 
dialysis eight times, had an aortic perforation that 
required suprarenal c amping of his aorta with pro- 
longed organ ischemia. The second patient, who 
required ialysis four times, had successful endolumi- 
nal repair of his aneurysm and bilateral iliac artery 
aneurysms but developed ischemia of his left leg after 
a complicated reconstruction was performed to rees- 
tablish flow through an iliofemoral bypass to the 
contralateral limb, which had had previous alvage 
procedures. Although there was perfusion of the limb 
after the reconstruction, the patient developed a
compartment syndrome that required a fasciotomy. 
His transient renal failure was caused by rhabdomy- 
olysis. The third patient, who required two dialysis 
treatments, had a creatinine l vel of 3.5 mg/dl before 
intervention and returned to this level after two 
dialysis essions. 
During the study there were three arterial injuries 
that required repair. Two of these injuries were the 
arterial perforations that have been described. The 
third was a dissection of the left iliac artery at the time 
of device deployment. This occurred at a point of 
previous narrowing of the vessel and was easily re- 
paired by placement of a 308 Palmaz stent. 
Blood loss during the procedures was directly 
Table I. Complications of aortic and 





Stroke, TIA 0 
Pulmonary 
Prolonged intubation 1 
Aspiration (death) 1 
Renal failure 
Transient ('l'Cr, BUN) 2 
Dialysis (2 to 8 times) 3 
Arterial injuries 
Perforations (1 aorta, 1 iliac) 2 
Dissections 1 iliac requiring 1 
stent repair 
Deaths 
Procedure-related (1 of 14, 7%) 
Rupture of chronic perforation 1 
Non-procedure related (2 of 14, 14%) 
Pulmonary aspiration i  1 
COPD patient at 17 days 
Complications of lower GI 1 
bleeding at 67 days 
Other 
Colon ischemia 1 
MI, Myocardial infarction; TIA, transient ischemic attack; Cr, 
creatinine; BUN, blood urea nitrogen; COPD, chronic obstructive 
pulmonary disease; GI, gastrointestinal. 
relatcd to the length of the intcrvention. Paticnts 
routinely were encouraged todonate one or two units 
of their own blood for reinfusion at the time of 
intervention. An in-line autotransfusion device was 
used to capture blood loss during the procedures. 
Reinfusion varied from 500 to 5000 ml in this study. 
Patients who successfully received endoluminal pros- 
theses and had uneventful recoveries usually required 
no additional transfusion, although two patients who 
had prolonged procedures received transfusions of 
banked packed red blood cells to replace the blood 
they lost during the procedure. 
Protocol modifications based on complica- 
tions and limitations. During the study the treat- 
ment protocol was modified as complications ornew 
problems presented (Table II). These changes high- 
light several important concepts and led to the con- 
clusions that were made in this preliminary series. The 
most dramatic evolution occurred in the treatment of
abdominal ortic aneurysms. The initial attempt was 
to select patients who could be treated with the 
insertion ofaortoaortic interposition tube grafts. This 
required the selection of individuals who had ad- 
equate diameter and length of proximal and distal 
aortic fixation sites. 
In the three patients who were treated in this 
manner, the procedures were difficult o accomplish 
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Table  I I .  Imaging data 
Patient Months after 
no. Procedure procedure 
Imaging methods 
Before During 
Angiography CT CF IVUS 
1 Tube aortic eudograft 15 
2 Tube aortic endograff Died 4 hr after 
procedure 
3 Iliac aneurysm exclusion 14 
4 Tube aortic endograft--aorto- 13 
bifemoral bypass 
5 Iliac aneurysm exclsuion Died 67 days after 
procedure 
6 Axillary artery pseudoaneurysm 11 
exclusion 
7 Profunda rtery arteriovenous l0 
fistula exclusion 
8 Aortic stenosis dilatation 9 
9 Aortoiliac exclusion of aortic 9 
aneurysm 
i0 Aortoiliac exclusion of aortic 9 
aneurysm 
i I Aortoiliac exclusion of aortic Died 17 days after 
aneurysm procedure 
12 Aortoiliac exclusion of aortic 8 
and iliac artery aneurysms 
13 Aortoiliac exclusion of aortic 8 
aneurysm 
14 Aortobifemoral bypass 7 
15 Axillary artery pseudoaneurysm 7 
exclusion 
16 Aortoiliac exclusion of aortic 7 
and iliac aneurysm 
17 Aortoiliac exclusion of aortic 6 
pseudoaneurysm 
X X X 
X X X X 
MRI X X X 
X X X X 
X X X X 
X X X 
X X X 
X X X X 
X Spiral X X 
X Spiral X X 
X Spiral X X 
X Spiral X X 
X Spiral X X 
Spiral X X 
X X X 
X Spiral X X 
X Spiral X X 
CF, Cinefluoroscopy; Spiral, shaded, surface-rendered spiral CT. 
with the bal loon-expandable devices. The first patient 
treated with this method was an 86-year-old high-risk 
woman who by cinefluoroscopy appeared to have 
complete xclusion o f  the aneurysm at the time o f  the 
procedure.  IVUS examination o f  the endograft  at the 
complet ion of  the study was not  possible for technical 
reasons. The fol low-up duplex scan at 1 month  and 
spiral CT  scan at 6 months demonstrated a small distal 
endoleak that communicated by a narrow channel 
with a patent inferior mesenteric artery. The dimen- 
sions o f  the ancurysm have been cont inuously ob- 
served, and the diameter emains at approximately 
5 cm, which correlates to the preintervenf ion CT 
scan, which measured the aneurysm at 5.2 cm. A 
secondary intervention to seal the leak has been 
offered, but  the patient declines t reatment at present. 
Fig. 1 demonstrates the appearance o f  the endoleak 
on a duplex ultrasound and CT scan. 
The second patient who was treated with an 
aortoaort ic  interposit ion endoluminal  replacement 
procedure was a 78-year-old high-risk man who had a 
chronic perforat ion of  his aorta on CT scan (Fig. 2). 
Dur ing the procedure,  the site o f  the perforat ion was 
identif ied by cinefluoroscopy and IVUS near the 
superior margin of  the inferior neck. An aortic inter- 
posit ion prosthesis was deployed, with complete x- 
clusion o f  the aneurysm conf irmed by cinefluoros- 
copy and IVUS at the end o f  the procedure.  Approxi-  
mately 3 hours after the intervention the patient 
became hypotensive; exploration was undertaken,  
and bleeding was found coming from a degenerated 
aneurysm wall in the r ight retroper i toneum. The 
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Imaging methods 
After 













Distal neck endoleak 
Bleeding from chronic perforation 
site 4 hr after procedure 
Dialysis x2 required to restore renal 
function to preintervention level 
Inadequate distal neck seal--per- 
forated iliac artery attempting clo- 
sure of endoleak 
Device maldeployment and prolonged 
procedure due to cinefluoroscopy 
overheating 
Aortic perforation by oversized 
balloon 
Rhabdomyolysis econdary to limb 
compartment syndrome 
IVUS determination fdistal neck 
>2 cm instituted as entry criterion 
Eliminate sites near chronic disrup- 
tions for device fixation or dilitation 
Preferentially use aortoiliac bypass. 
Rely on IVUS for distal neck 
assessment 
Close observation of fluoroscopy 
temperature--frame rate adjusted 
Protocol amended to use only bal- 
loons with 2 mm of the IVUS 
measured dimensions 
endovascular procedure was converted to an aorto- 
bifemoral bypass; however, the patient did not survive 
the surgery. The postmortem examination revealed a
degenerated posterior aspect o f  the abdominal aorta 
in the area that was the source of  the bleeding after 
intervention. The aneurysm had been excluded by the 
endograft, although it was suspected that balloon 
dilation of  the infrarenal neck had fractured the 
tenuous tissues and led to the retroperitoneal hemor- 
rhage. The protocol was modified at this interval to 
not choose sites near chronic disruptions for device 
fixation or mechanical dilatation. 
The third patient who was treated by an aortoaor- 
tic tube endograft appeared to have a 3-cm length 
proximal and distal aneurysm neck on the angiogram 
taken before intervention. The distal neck was mea- 
sured as 2.2 cm in length by axial images. At the time 
of  the intervention, IVUS interrogation of  the distal 
neck revealed that it was only 1.4 cm long. After 
deployment o f  the device, the cineangiogram sug- 
gested complete xclusion of  the aneurysm, whereas 
the IVUS demonstrated a leak (Fig. 3). During an 
attempt o further dilate the stent to obliterate the 
endoleak, the lilac artery was lacerated and the patient 
was converted to an aortobifemoral bypass. 
As a result o f  the difficulties that were encountered 
when performing the aortoaortic endoluminal pro- 
cedures and of  the very limited number  o f  patients 
that were candidates for this the type of  intervention, 
we began to use the technique of  aortoiliac bypass 
with occlusion of  the contralateral lilac artery and 
femorofemoral bypass that has been described by 
several investigators. 1,3,9 Fig. 4 demonstrates the 
spiral CT scans obtained from before and after the 
intervention in a successful aortoiliac, femorofemoral 
bypass procedure. Subsequent endoluminal bypasses 
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Fig. 1. A, Surface ultrasound image ofendoluminal graft at 3 months demonstrates an endoleak 
from distal end of device connecting to lower portion ofaneurysm. Aneurysm dimensions at time 
of exam had decreased from 5.2 cm before treatment to4.6 cm. Single arrow, distal stent; double 
arrows, aneurysm wall. B, Axial CT images acquired at 6 months demonstrate p rsistence of 
endoleak, with the superior mesenteric artery (arr0w on top image ) communicating via a channel 
(arrow on lower image) in the aneurysm to a leak around the distal stent. 
with this method were performed without procedure- 
related complications, aside from the one instance of 
limb ischemia nd transient renal failure that has been 
discussed in the patient who underwent a complex 
femorofemoral reconstruction that was required to 
establish distal perfusion, and the patient who was 
converted to conventional bypass because of an aortic 
perforation. The perforation was caused by using an 
oversized balloon for device expansion. The protocol 
was subsequently amended to use only balloons 
within 2 mm of the IVUS-measured size to prevent 
similar problems. 
The procedure time for the aortoiliac, femoro- 
femoral reconstruction technique was approximately 
31/2 to 4 hours if no problems were encountered. This 
interval includes approximately 1 hour to isolate the 
iliofemoral arteries to apply sufficient traction to 
remove excessive iliac tortuosity, which enables the 
passage of the devices from a femoral approach. 
Approximately 30 minutes was required for IVUS and 
cinefluoroscopy mapping of the dimensions and 
length of the diseased segment and endograft fixation 
sites. An additional 30 minutes was required to 
complete the fabrication of the prosthesis. Deploy- 
ment of the endoluminal device requires 30 minutes, 
with an additional 1 hour needed to perform the 
femorofemoral reconstruction, contralateral iliac ar- 
tery occlusion, and groin wound closures. Using this 
approach, uncomplicated procedures were completed 
with the patient receiving only autotransfused blood. 
Follow-up examination f  patients who received 
aortic endografts revealed that aneurysm dimensions 
stabilized or decreased in all excluded lesions. The 
greatest decrease in diameter was from 6.5 cm before 
the intervention to 3.0 cm at the 8-month evaluation 
in one patient. 
Results o f  t reatment of  traumatic lesions. The 
second group of interventions that were performed in 
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Fig. 2. Composite photograph of predeployment and postdeployment images from patient 
who had contained perforations ofaorta. The preintervention images demonstrate preinterven- 
tion angiogram (left), axial CT scans from levels represented demonstrating chronic perforation 
indicated by arrows (center), and IVUS images from positions hown (right). The postdeploy- 
ment images demonstrate contrast cinefluoroscopy (left), and longitudinal gray-scale recon- 
struction &igbt) of axial 1VUS images along the lesion depicts isolation of the aneurysm by the 
endograft. 
PRE-DEPLOYMENT POST-DEPLOYMENT 
Fig. 3. Composite photograph ofpredeployraent a d postdeployment images from abdominal 
aortic aneurysm that appeared to have an ideal neck for interposition aortoaortic endograft 
placement on preintervention a giogram and CT scan (leftand middleimages on preintervention 
panel). Axial IVUS images of same levels shown on CTs are displayed. IVUS evaluation 
demonstrated that length of neck was 1.4 cm, rather than 3.0 or 2.2 cm as measured on 
angiogram and CT, respectively. Postdeployment panels show contrast cinefluoroscopy that 
suggests complete sealing of aneurysm from the endograft lumen, but IVUS demonstrated 
persistent endoleak (arrow) that was not able to be closed by further interventions. 
this study were in patients who had traumatic arterio- 
venous fistulas or pseudoaneurysms of  the axillary and 
profunda arteries. In these instances, the real-time 
ultrasound deployment technique was used as the 
primary imaging method and was supplemented with 
contrast cinefluoroscopy use only at the beginning 
and completion of the procedure to obtain assured 
exclusion of the arterial injuries and to acquire control 
images for comparison with other imaging methods 
(Fig. 5). 
Follow-up evaluation of the three patients who 
were treated for traumatic injuries reveals that the two 
axially artery repairs are patent by surface ultrasound 
imaging evaluations at 3 months and 6 months. The 
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Fig. 4. Composite photograph of spiral CT before intervention (left), with corresponding 
longitudinal 2-D reconstruction (center), and 3-D spiral CT reconstruction of aortoiliac 
exclusion ofaneurysm after procedure (right). Longitudinal 2-D image demonstrated exclusion 
of aneurysm (single arrow) by endoluminal graft. 3-D reconstruction after procedure demon- 
strates no flow in aneurysm sac with occlusion of contralateral iliac artery by endoluminal 
occluder (double arrows). Femorofemoral reconstruction is not demonstrated onthis photo- 
graph. 
third patient, who had a profunda artery-to-deep 
femoral vein arteriovenous fistula was referred for 
cndoluminal graft treatment after failures to occlude 
the large arteriovcnous fistula by conventional coil 
embolization techniques. The arteriovenous fistula 
was easily excluded with the ultrasound-guided n- 
doluminal prosthesis deployment method using a 
composite autogenous vein/stent prosthesis. In this 
patient, the profunda rtery distal to the fistula had 
been thrombosed for 4 days before endograft place- 
ment and rethrombosed l0 days after the interven- 
tion. In addition, an arteriovenous fi tula that devel- 
oped from a branch of the circumflex femoral artery 
was embolized to complete treatment of the lesion. 
The occlusion of the profunda rtery was accommo- 
dated without problems, and the patient's ABI after 
the procedure was 1.0. 
DISCUSSION 
Endoluminal vascular prostheses are being evalu- 
ated with variable monitoring mechanisms in many 
countries. Because there are limited supplies of com- 
mercially available product for investigation, the ma- 
jority of U.S. investigations are being conducted by 
physicians who are assembling devices with commer- 
cially available vascular stents and vascular prostheses. 
In many of the early studies, the feasibility for using 
this technology to exclude aneurysms and arterio- 
venous fistulas with short-term and intermediate- 
term success has been demonstrated) 'a'9 Significant 
morbidity and mortality rates also have been associ- 
ated with these procedures, particularly in high-risk 
patients. 
Endoluminal grafts are also being used to treat 
occlusive vascular lesions with variable, yet promising 
potential.i° In both the aneurysm and occlusive lesion 
applications, the eventual utility may be significant if
the device and delivery system li itations associated 
with current prototypes can be overcome. Eventual 
long-term utility also relies on demonstrating that 
exclusion of aneurysms with endoluminal prostheses 
fulfills the expectations of decreased morbidity and 
mortality rates, lower hospital costs, and long-term 
exclusion ofaneurysms with rupture prevention. The 
occlusive arterial applications are confronted with 
more challenging issues in that the devices must attain 
long-term patency rates similar to those of conven- 
tional bypass procedures. 
One hypothesis of this FDA-approved Investiga- 
tor Feasibility Study was that all patients who were 
candidates for treatment with endoluminal prostheses 
could be entered in a prospective manner to deter- 
mine the utility of this technology and to identify 
issues requiting further development in a safe and 
ethical manner. With these methods, we have been 
able to successfully offer an alternative treatment for 
high-risk patients with morbidity and mortality rates 
comparable with those reported in contemporary 
series of surgical patients with similar isks. The major 
problems encountered in the procedural and postop- 
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Fig. 5. Compositc photograph of pretreatmcnt and posttreatment images acquired during 
1VUS-guided eployment ofcndoluminal graft o treat ~irteriovenous fistula of right axillary 
artery after gunshot injury. IVUS images acquired at beginning of procedure vealed dimensions 
of proximal and distal artery and length of i jury to vessel. Corresponding duplex surface 
gray-scale surface ultrasound image of lesion before beginning intervention demonstrates 
arteriovenous connection. Postdeployment angiogram demonstrates complete isolation and 
exclusion of arteriovenous fistula, which is confirmed by IVUS inspection and postprocedurc 
gray-scale surface duplex imaging of device. 
erative care ofthese patients were related to technical 
aspects of the procedures, uch as the two arterial 
perforations that have been addressed by modifica- 
tions in the protocol. This limitation is resolved by 
using a range of balloon sizes that have recently 
become available and enable deployment ofthe larger 
stents while minimizing the risk of arterial overdis- 
tention and perforation. 
The causes of the two deaths that occurred in the 
first 30 days after the procedures will likely be avoided 
in subsequent studies by ongoing technical advances. 
In the patient who died after surgery from hemor- 
rhage from a contained chronic rupture, successful 
treatment may have been accomplished by minimiz- 
ing manipulation ofthe chronic perforation site and 
avoiding dilation of the distal neck by performing an 
aortoiliac exclusion. The postmortem examination 
revealed that the distal stent probably disrupted the 
contained rupture in the retroperitoneum, initiating 
the hemorrhage even though the aneurysm had been 
shown to be excluded from the vessel umen on 
completion cineangiogram and IVUS examinations. 
Aortoiliac exclusion or the use of an aortoiliac device 
to avoid dilation of the origin of the chronic perfora- 
tion in the distal neck might have alleviated this 
problem. 
The second death after intervention was from 
aspiration in a patient who had chronic obstructive 
pulmonary disease who was otherwise recovering as 
anticipated from the endoluminal exclusion proce- 
dure. Although the aspiration was an unforseen event, 
the complication could possibly have been avoided by 
shortening the length of the procedure, thus enhanc- 
ing the speed of his recovery. In the future, more 
expedient devices (i.e., low-profile bifurcated pros- 
theses) will enable reduced time for the deployment. 
The second hypothesis in this studywas that IVUS 
imaging would enhance the precision of the proce- 
dures. This report highlights the potential oflVUS as 
the primary method to identify the location and 
quantitate he dimension and length of fixation sites 
for endoluminal prostheses deployment and to deter- 
mine the required length of the fixation sites for 
endoluminal device. The use of contrast cinefluoros- 
copy in many of the procedures was limited to 
confirming the IVUS observations regarding the 
morphologic features and the location of lesions, to 
identify associated vascular structures, and to confirm 
JOURNAL OF VASCULAR SURGERY 
568 White et al. October 1996 
the location of the prosthesis and document vascular 
continuity after completion of the deployment. 
The use of BzUS in this manner has changed our 
protocol for performing endovascular g afting proce- 
dures. After crossing the lesion with a guidewire 
under the guidance ofcinefluoroscopy, IVUS is used 
initially as the primary method to interrogate the 
length of the lesion for luminal morphologic features, 
to determine measurements of dimensions, and to 
identify branch arteries, such as the renal arteries. 
Contrast cinefluoroscopy is used to confirm the IVUS 
observations, thus limiting the use of contrast agent 
and road-mapping during the procedure. After de- 
ployments, both contrast cinefluoroscopy and IVUS 
are used to interrogate the length of the repair to 
assure sealing of the aneurysm. 
Other relevant observations regarding the imag- 
ing methods used in this protocol are that the 
angiographic and cinefluoroscopic examinations be- 
fore the intervention were misleading in patients early 
in the study regarding critical determinants ofpatient 
candidacy and device deployment. As described, an- 
giography frequently suggested the presence of a 
distal neck for placement of an aortoaortic prostheses 
in AAAs, whereas CT and IVUS were more accurate 
in making this determination. After recognizing this 
phenomenon, CT and particularly IVUS at the time 
of the intervention became the primary way to deter- 
mine luminal morphologic features and dimensions 
for device sizing and secure device deployment. 
Dimensional information derived from both cine- 
fluoroscopy and angiography was limited by inaccu- 
racies produced by image magnification, parallax, and 
uniplanar views. Cinefluoroscopy was used in all cases 
and was particularly tlseful for determining the con- 
tinuity of vascular structures and the anatomy of 
branch arteries and for enabling the precise position- 
ing of stents. MRI also was helpful for determining 
the size of the aorta and aneurysms, particularly in 
individuals who had renal compromise, but overesti- 
mated the hemodynamic significance of occlusive 
lesions in the iliac and femoral arteries. 
Duplex scanning was very helpful in assessing and 
precisely identifying the location of arteriovenous 
fistulas and provided follow-up without requiting 
more costly and invasive imaging methods. Three- 
dimensional reconstruction imaging technologies 
such as spiral CT were particularly helpful for assess- 
ing the morphologic features of vascular anatomy 
before the intervention and at follow-up intervals, 
whereas 3-D IVUS provided a similar real-time per- 
spective during the procedure. 
Frequently suggested potential advantages ofthe 
endoluminal repair of vascular lesions include the 
less-invasive nature of procedures, hortened hospi- 
talization , and lower cost. In this feasibility study, the 
average length of hospitalization of 6 days does not 
reflect he actual needed length of stay, as several of 
the patients were observed beyond the requirement 
for admission to evaluate and observe progress. Be- 
cause of the early stage of development of this 
technology, no attempt to minimize hospital stay or 
cost was made, so evaluation of these anticipated 
benefits will occur in later studies. 
This report emphasizes the potential utility of 
endoluminal prostheses, but the initial enthusiasm 
must be tempered by the significant morbidity and 
mortality rates and by the limited follow-up of these 
developing methods. In addition, surgical conversion 
was needed in two patients on an urgent basis to repair 
arterial perforations, emphasizing the need to have 
patients prepped and draped for conversion to a 
conventional surgical repair, if required. 
CONCLUSIONS 
After completion of this preliminary evaluation, 
we conclude that the aortoaortic endovascular inter- 
positions are not possible using a balloon expandable 
device like the one used in this study in the majority of 
patients who have abdominal aortic aneurysms. Aor- 
toiliac bypass, contralateral iliac artery occlusion, and 
femorofemoral bypass is an acceptable alternative in 
most patients. In addition, it appears that the aneu- 
rysm size stabilizes or becomes smaller after successful 
exclusion of the aneurysm. In this limited series, 
endoluminal prostheses were also found to be useful 
for treating iliac artery aneurysms and traumatic 
arterial lesions in patients who qualified for the study. 
A combination of contrast CT images (preferably 
surface-rendered spiral reconstruction) before and 
after intervention and 1VUS during procedures 
supplemented by contrast cinefluoroscopy enables 
patient selection and the precise deployment of en- 
dograft devices and is an alternative to established 
cineangiography methods. IVUS-monitored posi- 
tioning and deployment is possible in vessels less than 
20 mm in diameter using current 20 and 30 MHz 
imaging catheters. 
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DISCUSSION 
Dr. E. John Harris, Jr. (Stanford, Calif.). Dr. White 
and his associates have presented a preliminary status report 
of their FDA-approved, investigator-sponsored study of 
endoluminal vascular therapies for aneurysmal disease, 
occlusive disease, and traumatic arteriovenous fi tulae. The 
primary goal of this report was to evaluate the various 
imaging methods for their abilities to evaluate candidates 
for, and to evaluate the deployment and follow-up of, 
endoluminal grafts in these three groups of patients. In 
addition, the short-term results are presented for 13 pa- 
tients who had aneurysmal disease, three patients who had 
arteriovenous fistulae, and one patient who had aortic 
occlusive disease. 
I would like to commend Dr. White for his honesty and 
accuracy in presenting the significant short-term orbidity 
and mortality rates in these mostly high-risk patients. At 
Stanford, we have a similar study underway, and we have 
observed similar rates of morbidity and mortality, almost 
exclusively in patients who had aneurysmal disease. The 
authors hopefully suggest that refinements in the deploy- 
ment systems and stent/graft designs will decrease these 
rates over rime as bad outcomes drive the revision process. 
I am less optimistic, and I hasten to point out the traditional 
method of open aneurysmorrhaphy, in 1996, remains 
successful and durable with low morbidity and mortality 
rates. Dr. Ron Dalman and I recently reviewed our aneu- 
rysm results ince we began our practice at Stanford and the 
Palo Alto Veterans Hospital. There were 73 consecutive 
patients, all male and mostly veterans, with a mean age of 70 
years; 30% were older than 75 years. They, too, were 
high-risk patients, with a third undergoing concomitant 
revasculatizations of renal arteries or legs. There were no 
deaths, no prolonged intubations, and no episodes of renal 
failure that required ialysis. I review this data not to side 
with one of the combatants in the upcoming Porter-Fogarty 
shootout, as I have worked closely with both, and I agree 
with many of the viewpoints expressed by both men. I 
emphasize that the traditional method ofaneurysm repair is 
safe and effective and that the development ofnew methods 
of aneurysmorrhaphy requires a commitment to carefully 
perform and evaluate these new therapies honestly, as 
evidenced by this report from Dr. White and his associates. 
I would like to focus the remaining discussion on the 
comparative utility and accuracy of the imaging methods 
presented in this report. Thirty-one patients were evaluated 
for inclusion in the study, and only 17 patients fulfilled the 
entry criteria, which were not completely described. For 
aortoiliac lesions, CT scans provided the most valuable 
preoperative information, and IVUS with cinefluoroscopy 
assistance provided the most useful intraoperative informa- 
tion. Follow-up with CT scans or Duplex scans was suitable. 
For the traumatic arteriovenous fi tulae, Duplex scans were 
successful for preoperative localization and IVUS-guided 
deployment. For the fistulae, a 30 MHz probe could be 
positioned in the deployment assembly to guide real-time 
delivery and expansion of the stents. For aortoiliac lesions, 
real-time IVUS guidance was not possible; rather, a 12- or 
20-MHz probe was used to define the target morphologic 
features before deployment, was removed during stent 
deployment, and then was reinserted to visualize the success 
of stent placement after removal of the delivery system. 
There were three arterial injuries during aortoiliac proce- 
dures, two of which were directly related to reinflation of the 
deployment balloon after partial attachment of the stent at 
the target site. It appears that these injuries might have been 
avoided with real-time IVUS guidance. The 30-MI-Iz probe 
obviously is low profile but provides high resolution in a 
very near field, and thus is not suitable for aortic and iliac 
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work. This brings me to my questions for the authors: Are 
there any low profile 12- to 20-MHz probes on the horizon? 
Do the authors believe that IVUS is the key to successful 
deployment of endoluminal stent grafts? In the authors 
growing experience with IVUS, are there specific morpho- 
logic patterns that predict successful or unsuccessful deploy- 
ment ofstent grafts? In review of the failed procedures and 
their preoperative imaging studies, are there any clues that 
suggest unfavorable deployment ofthe stent/grafts? Do the 
authors believe that recently developed MRI flow data, 
specifically flow fields within the aneurysms, will aid in the 
development and delivery of the endoluminal prostheses? 
In spite of my apparent pessimism, I remain interested 
in the development of this new and rapidly developing 
therapeutic method. I look for continued information, both 
positive and negative, to emerge fromongoing work such as 
that represented in Dr. White's report. 
Dr. Rodney A. White. Intravascular ultrasound real- 
time deployment is a very powerful technique. Ten- and 
twelve-megahertz catheters will be eventually developed 
that will be guidewire-size. These wires then will be used as 
components ofthe imaging and delivery systems expediting 
the precision of deployments. 
Your observation regarding the need for precise imag- 
ing when deploying balloon-expandable devices is correct. 
We rely on IVUS to provide this information because 
cinefluoroscopy is frequently inadequate to demonstrate 
when the device is apposed to the vessel wall. In most cases, 
we have a tendency to slightly overdilate the device to assure 
fixation. This has a potential adverse effect of causing 
continued ilation of the aneurysm neck. The tendency to 
overdilate also increases the risk of vessel perforation, a
problem that we encountered on one occasion. We look to 
IVUS to resolve this problem when real-time deployment 
becomes available in the larger-vessel delivery systems. 
The morphology data provided by IVUS is very impor- 
tant. We make our final patient and device selection on the 
basis of the IVUS interrogation ofthe lesion either before or 
during the procedure by choosing the stent-fixation sites, 
determining plaque morphologic features and distribution 
and measuring vessel dimensions. 
The magnetic resonance flow and angiographic data 
may eventually be very helpful in patient selection. We have 
used MRI to evaluate patients who had contraindications to 
contrast imaging studies (i.e, renal failure, etc.) and find it 
useful in the early screening process. At present, the 
morphologic and dimensional data provided by MRI are 
not as useful as those provided by CT or IVUS. The 
long-term utility of MRI awaits further investigation. Con- 
trast CT before and after the intervention and IVUS during 
the procedures are the most useful imaging methods at the 
present time. 
IVUS is a particularly good alternative for surgeons 
because it provides a reliable and relatively inexpensive 
alternative to obtain precise imaging in the operating room, 
particularly when high-resolution x-ray equipment is not 
available and new acquisitions require major capital expense 
and time delays. A combination of good-quality cinefluo- 
roscopy and IVUS enables precise delivery of devices and 
can be acquired in a reasonable time frame. 
Dr. Robert B. Rutherford (Denver, Colo.). You 
already started to address the question that I had in mind, 
which was that one of your major goals here was to evaluate 
IVUS, but I don't hink you took time to explain to us what 
your specific riteria nd endpoints for evaluating its efficacy 
were and which were positive. Also, was this evaluation 
performed in some blinded fashion, where different people 
evaluated the end results? The details of the evaluation 
didn't come out in your presentation, but I would be very 
interested in them. I think that it is a very important aspect 
of your study. 
Dr. White. The only comparison data that are available 
are measurements of morphologic features and vessel sizes 
at comparable l vels. The patients included in this study 
were chosen on the basis of CT and angiogram studies. In 
this setting, a blind evaluation of imaging methods is not 
possible because the patients were chosen with predeter- 
mined criterion using studies with variable quality. In 
addition, not all patients have the same imaging studies. 
The FDA is very interested in being able to define 
appropriate selection criterion, indicators for the success or 
failure of devices, and in developing ways to pool data from 
various investigators to reach reasonable conclusions. The 
attempt in this study was to determine some of these 
variables from the data we collected. 
Dr. Wesley S. Moore (Los Angeles, Calif.). First of all, 
I would like to emphasize something that the author said 
right at the beginning but that may not be clear to the 
audience. The work that they are doing is being done under 
the auspices of an FDA-approved protocol. That is no small 
achievement. 
Until this current study there has only been one 
FDA-approved protocol for endovascular grafting. That 
study is being very carefully controlled, very carefully 
looked at, and the data reported with a great deal of 
accuracy. 
In spite of that, there are several implant programs, not 
only in this country but abroad, in which the data are really 
retrospectively reviewed and the accuracy-or the reporting 
of the complication rate is probably not as good as we would 
like it. 
In contrast to those studies, what we have heard today 
really is in the context of an FDA-approved protocol. The 
results that we have heard reflect he kind of accuracy that 
will occur when the FDA holds your hand to the fire to make 
sure that all of the data arc carefully collected and reported. 
I would like to commend the authors for having taken the 
time and the effort to secure FDA approval before going 
ahead and proceeding with this kind of study. 
Having said that, I would like to just ask one question 
or make a couple of comments. Number one, I 'm a little bit 
concerned about he fact that angiography is not a routine 
requirement inselecting your patients. I agree with you that 
ultrasonography is aterrific adjunct and may very well give 
you data that are not available on an angiographic s an. On 
the other hand, the angiogram occasionally will reveal data 
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that will make the deployment of these devices perhaps less 
desirable, and I'll give you a couple of examples. 
Angiography is a requirement, as you know, in our 
protocol, and the very first patient that we had served up on 
the basis of CT scan who we thought was going to be an 
ideal candidate for endovascular repair turned out to have a 
renal artery coming right off his aortic bifurcation. That 
would have been a real problem had we gone ahead without 
an angiogram. 
We have also seen a number of instances in which there 
was mesenteric arterial occlusive disease as revealed by a 
meandering mesenteric artery, indicating that the inferior 
mesenteric artery is an important contributor to blood flow. 
On the basis of that experience, we have gone ahead with 
elective conventional repair as opposed to endovascular 
repair. 
We have seen a myriad of patients who had renal artery 
stenoses, and clearly that condition is not going to be 
addressed by an endovascular p ocedure unless you want to 
go ahead and try to perform balloon angioplasty. So I think 
it is worthwhile getting preoperative angiograms of these 
patients to be able to sort out associated conditions that may 
be better served by conventional operation. 
I would take issue with your statement concerning the 
utility of tube graft repair, or as you call it, in-line repair of 
aneurysm. It is true that not many patients are candidates. 
In our series, it is about one out of seven. However, in those 
one out of seven, it's a lot easier to perform a tube grafting 
procedure rather than to put in a modified graft as you've 
proposed itwith a femorofemorai graft Or certainly to put in 
a bifurcated graft, and I think it's worthwhile looking for 
those candidates and using tube grafts when we can. 
Dr. White. I appreciate you insight and supportive 
comments. We rely on spiral CT to supply the information 
that usually is obtained from angiograms. I f  we didn't have 
spiral CT available, we would need an angiogram. 
We also rely on IVUS during the procedure to identify 
the renal and mesenteric arteries. We currently delay con- 
trast studies until we have interrogated the lesion with IVUS 
and only use contrast cinefluoroscopy to confirm the IVUS 
observations. 
We are not selecting patients on the basis ofpatency of 
the inferior mesenteric artery, but rather on the status of the 
hypogastric arteries. If  the hypogastric arteries are patent 
and can be maintained during the revascularization proce- 
dure, we consider this the primary determinant for prevent- 
ing visceral ischemia. In addition, we frequently inspect the 
celiac and superior mesenteric artery orifices with IVUS and 
would persist in this evaluation if there was a question of 
visceral compromise. 
Dr. Kenneth E. McIntyre, Jr. (Galveston, Tex.). I am 
a little concerned about the necessity for the femoro- 
femoral bypass. The patency results for femorofemoral 
bypass procedures performed for occlusive disease are not 
encouraging. 
Although you don't have data now, do you think over 
the long haul that you will have to revise many femoro- 
femoral bypass grafts? Will that be a better alternative to 
in-line grafts? 
Dr. White. I think an in-line graft would be the ultimate 
solution. When a bifurcated graft becomes available it will 
obviously offer a solution to this problem. 
Patients who have significant outflow problems are not 
entered into the protocol unless there is an acceptable 
alternative that can be incorporated as part of the proce- 
dure. In general, this has not been a problem because the 
patients that are selected have aneurysmal rather than 
occlusive lesions. 
At present, aortoiliac bypass seems to be a durable 
alternative. Our experiment and those of others, including 
the Australian experience of 4 years' follow-up, supports 
this alternative as a viable option. 
